Public Employees Retirement System of Ohio reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.6% in the second quarter, HoldingsChannel.com reports. The firm owned 209,427 shares of the biotechnology company’s stock after selling 5,646 shares during the period. Public Employees Retirement System of Ohio’s holdings in Exelixis were worth $4,475,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Tiverton Asset Management LLC raised its holdings in shares of Exelixis by 42.2% during the second quarter. Tiverton Asset Management LLC now owns 23,348 shares of the biotechnology company’s stock worth $499,000 after purchasing an additional 6,931 shares during the last quarter. Riverhead Capital Management LLC raised its position in Exelixis by 5.7% in the second quarter. Riverhead Capital Management LLC now owns 32,543 shares of the biotechnology company’s stock worth $695,000 after acquiring an additional 1,743 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Exelixis in the second quarter worth about $3,506,000. Sargent Investment Group LLC raised its position in Exelixis by 0.4% in the second quarter. Sargent Investment Group LLC now owns 432,125 shares of the biotechnology company’s stock worth $9,235,000 after acquiring an additional 1,685 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Exelixis by 40.7% in the second quarter. Renaissance Technologies LLC now owns 13,454,473 shares of the biotechnology company’s stock worth $287,522,000 after acquiring an additional 3,889,200 shares in the last quarter. 77.41% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Peter Lamb sold 217,404 shares of the company’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $20.59, for a total transaction of $4,476,348.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George A. Scangos sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.58, for a total value of $863,200.00. Following the transaction, the director now owns 1,168,031 shares of the company’s stock, valued at $25,206,108.98. The disclosure for this sale can be found here. In the last three months, insiders sold 584,926 shares of company stock valued at $12,117,223. 4.50% of the stock is currently owned by company insiders.
Shares of NASDAQ EXEL traded up $0.18 during trading hours on Friday, hitting $19.44. The stock had a trading volume of 527,675 shares, compared to its average volume of 2,867,352. The company has a market capitalization of $5.83 billion, a P/E ratio of 13.59 and a beta of 2.04. The firm’s 50-day moving average price is $20.28 and its two-hundred day moving average price is $21.26. Exelixis, Inc. has a 52 week low of $13.42 and a 52 week high of $25.31. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.53 and a current ratio of 8.64.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.02. The business had revenue of $240.28 million during the quarter, compared to analysts’ expectations of $226.97 million. Exelixis had a return on equity of 31.31% and a net margin of 70.52%. The firm’s quarterly revenue was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.31 EPS. As a group, analysts expect that Exelixis, Inc. will post 0.92 EPS for the current fiscal year.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: How dollar cost averaging works
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.